{"organizations": [], "uuid": "56f91e2074858451ac18cfd80002d674bfcf5df4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180507.html", "section_title": "Archive News &amp; Video for Monday, 07 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aptose-biosciences-says-exercises/brief-aptose-biosciences-says-exercises-early-option-for-cg-806-license-from-crystalgenomics-idUSFWN1SE0DH", "country": "US", "domain_rank": 408, "title": "Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.024, "site_type": "news", "published": "2018-05-07T19:08:00.000+03:00", "replies_count": 0, "uuid": "56f91e2074858451ac18cfd80002d674bfcf5df4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aptose-biosciences-says-exercises/brief-aptose-biosciences-says-exercises-early-option-for-cg-806-license-from-crystalgenomics-idUSFWN1SE0DH", "ord_in_thread": 0, "title": "Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics", "locations": [], "entities": {"persons": [], "locations": [{"name": "korea", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "crystal genomics inc", "sentiment": "negative"}, {"name": "aptose biosciences says exercises", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 7 (Reuters) - Crystal Genomics Inc:\n* APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS\n* APTOSE BIOSCIENCES INC - CO OWNS GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE CG-806 FOR ALL INDICATIONS OUTSIDE OF KOREA AND CHINA - LICENSED TERRITORY\n* APTOSE BIOSCIENCES- CRYSTALGENOMICS ELIGIBLE FOR REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS ROYALTIES ON PRODUCT SALES IN LICENSED TERRITORY\n* APTOSE BIOSCIENCES INC - OPTION EXERCISE TRIGGERS A PAYMENT OF US $2.0 MILLION TO CRYSTALGENOMICS Source text for Eikon:\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-07T19:08:00.000+03:00", "crawled": "2018-05-08T16:51:34.038+03:00", "highlightTitle": ""}